Trial reportHaematologica2017
Prognostic and biologic significance of long non-coding RNA profiling in younger adults with cytogenetically normal acute myeloid leukemia.
Open access · goldAbstract readClinical Trial
In one paragraph
Trial report in Haematologica, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
0numbers the graph read from it
0cells of the map it votes in
23citing papers in PubMed
1.8field-weighted citation impact, top 16% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 39 citations in OpenAlex.
- Distinct clinical and biological characteristics of acute myeloid leukemia with higher expression of long noncoding RNA KIAA0125.Annals of hematology · 2021Trial
- Comprehensive lincRNA Transcriptome in Acute Myeloid Leukemia: Integrating Known and Newly Identified lincRNAs Across Pediatric and Adult Cohorts.Non-coding RNA · 2026Article
- MALNC: a new mutant NPM1/IDH2Cancer gene therapy · 2025Article
- LncRNAiScience · 2025Article
- Prime-time for LncRNA signatures in acute myeloid leukemia?Annals of hematology · 2025Review
- XPO1/Exportin-1 in Acute Myelogenous Leukemia; Biology and Therapeutic Targeting.Biomolecules · 2025Review
- Circular RNAs: pivotal role in the leukemogenesis and novel indicators for the diagnosis and prognosis of acute myeloid leukemia.Frontiers in oncology · 2023Review
- Clinical and molecular relevance of genetic variants in the non-coding transcriptome of patients with cytogenetically normal acute myeloid leukemia.Haematologica · 2022Article
- Non-coding RNAs: are they the protagonist or antagonist in the regulation of leukemia?American journal of translational research · 2022Review
- Gene expression signature predicts relapse in adult patients with cytogenetically normal acute myeloid leukemia.Blood advances · 2021Article
- Long Non-Coding RNA LINC00152 Regulates Self-Renewal of Leukemia Stem Cells and Induces Chemo-Resistance in Acute Myeloid Leukemia.Frontiers in oncology · 2021Article
- The Role ofCancers · 2020Review
- Aberrant LncRNA Expression in Leukemia.Journal of Cancer · 2020Review
- Chidamide Inhibits Acute Myeloid Leukemia Cell Proliferation by lncRNA VPS9D1-AS1 Downregulation via MEK/ERK Signaling Pathway.Frontiers in pharmacology · 2020Article
- The long non-coding RNA HOXB-AS3 regulates ribosomal RNA transcription in NPM1-mutated acute myeloid leukemia.Nature communications · 2019Article
- Expression and functional relevance of long non-coding RNAs in acute myeloid leukemia stem cells.Leukemia · 2019Article
- Incorporation of long non-coding RNA expression profile in the 2017 ELN risk classification can improve prognostic prediction of acute myeloid leukemia patients.EBioMedicine · 2019Article
- Prognostic and Clinicopathological Significance of MiR-155 in Hematologic Malignancies: A Systematic Review and Meta-analysis.Journal of Cancer · 2019Review
- High expression of Linc00959 predicts poor prognosis in breast cancer.Cancer cell international · 2019Article
- The Regulatory Roles of Long Noncoding RNAs in Acute Myeloid Leukemia.Frontiers in oncology · 2019Review
Corrections and comments
- Commented on by
Authors and funding
21 authors at 8 institutions in 2 countries.
Dimitrios PapaioannouThe Ohio State University Comprehensive Cancer Center, Columbus, OH, USA.
Deedra NicoletThe Ohio State University Comprehensive Cancer Center, Columbus, OH, USA.
Stefano VoliniaDepartment of Morphology, Surgery and Experimental Medicine, University of Ferrara, Italy.
Krzysztof MrózekThe Ohio State University Comprehensive Cancer Center, Columbus, OH, USA.
Pearlly YanThe Ohio State University Comprehensive Cancer Center, Columbus, OH, USA.
Ralf BundschuhDepartment of Physics, Department of Chemistry & Biochemistry, Division of Hematology, Department of Internal Medicine, Center for RNA Biology, The Ohio State University, Columbus, OH, USA.
Andrew J CarrollDepartment of Genetics, University of Alabama at Birmingham, AL, USA.
Jessica KohlschmidtThe Ohio State University Comprehensive Cancer Center, Columbus, OH, USA.
William BlumThe Ohio State University Comprehensive Cancer Center, Columbus, OH, USA.
Bayard L PowellThe Comprehensive Cancer Center of Wake Forest University, Winston-Salem, NC, USA.
Geoffrey L UySiteman Cancer Center, Washington University School of Medicine, St. Louis, MO, USA.
Jonathan E KolitzHofstra North Shore-Long Island Jewish School of Medicine, Lake Success, NY, USA.
Eunice S WangRoswell Park Cancer Institute, Buffalo, NY, USA.
Ann-Kathrin EisfeldThe Ohio State University Comprehensive Cancer Center, Columbus, OH, USA.
Shelley J OrwickThe Ohio State University Comprehensive Cancer Center, Columbus, OH, USA.
David M LucasThe Ohio State University Comprehensive Cancer Center, Columbus, OH, USA.
Michael A CaligiuriThe Ohio State University Comprehensive Cancer Center, Columbus, OH, USA.
Richard M StoneDana-Farber Cancer Institute, Harvard University, Boston, MA, USA.
John C ByrdThe Ohio State University Comprehensive Cancer Center, Columbus, OH, USA.
Ramiro GarzonThe Ohio State University Comprehensive Cancer Center, Columbus, OH, USA ramiro.garzon@osumc.edu clara.bloomfield@osumc.edu.
Clara D BloomfieldThe Ohio State University Comprehensive Cancer Center, Columbus, OH, USA ramiro.garzon@osumc.edu clara.bloomfield@osumc.edu.
The Ohio State University · USHarvard University · USMayo Clinic · USRoswell Park Comprehensive Cancer Center · USUniversity of Alabama at Birmingham · USUniversity of Ferrara · ITWake Forest University · USWashington University in St. Louis · US
Funding
Member Site CoreU10CA180821 · NCI · BRIGHAM AND WOMEN'S HOSPITAL · PI Evanthia Galanis, Olwen Hahn · 2014 to 2026
$177.3MTranslational Therapeutics Research Program (TT)P30CA016058 · NCI · OHIO STATE UNIVERSITY · PI Jennifer A. Woyach · 1985 to 2026
$132.3MStatistics CoreU10CA180882 · NCI · MAYO CLINIC ROCHESTER · PI Sumithra Jay Mandrekar · 2014 to 2026
$115.0MTHE ALLIANCE NCTN BIOREPOSITORY AND BIOSPECIMEN RESOURCEU24CA196171 · NCI · WASHINGTON UNIVERSITY · PI Mine Cicek, Wendy Frankel · 2015 to 2026
$35.0MSPORE Leukemia Tissue BankP50CA140158 · NCI · OHIO STATE UNIVERSITY · PI MARCUCCI, GUIDO · 2009 to 2013
$11.2MOSU as Network Lead Academic Participating Site for the NCI NCTNU10CA180850 · NCI · OHIO STATE UNIVERSITY · PI BLUM, KRISTIE A, CHAKRAVARTI, ARNAB · 2014 to 2018
$6.8MTargeted Therapy for LeukemiaR35CA197734 · NCI · UNIVERSITY OF CINCINNATI · PI BYRD, JOHN C. · 2015 to 2021
$6.6MCancer and Leukemia Group B - The Ohio State UniversityU10CA077658 · NCI · OHIO STATE UNIVERSITY · PI BLOOMFIELD, CLARA D · 1998 to 2013
$6.0MITSC for Leukemia: Novel Molecular Strategies for NCTN: "Individualized" TherapieU10CA180861 · NCI · OHIO STATE UNIVERSITY · PI BLOOMFIELD, CLARA D, MARCUCCI, GUIDO · 2014 to 2018
$3.4MUltra-Low and Single-Cell Transcriptome Analysis in Patient-Derived Rare CLL Precursor CellsR50CA211524 · NCI · OHIO STATE UNIVERSITY · PI YAN, PEARLLY · 2016 to 2020
$745kNCI NIH HHS P30 CA016058NCI NIH HHS P50 CA140158NCI NIH HHS R35 CA197734NCI NIH HHS R50 CA211524NCI NIH HHS U10 CA077658NCI NIH HHS U10 CA180821NCI NIH HHS U10 CA180850NCI NIH HHS U10 CA180861NCI NIH HHS U10 CA180882NCI NIH HHS U24 CA196171
Abstract
Long non-coding ribonucleic acids (RNAs) are a novel class of RNA molecules, which are increasingly recognized as important molecular players in solid and hematologic malignancies. Herein we investigated whether long non-coding RNA expression is associated with clinical and molecular features, as well as outcome of younger adults (aged <60 years) with
Indexed as
AdultCytogenetic AnalysisDisease-Free SurvivalHumansLeukemia, Myeloid, AcuteMiddle AgedNucleophosminPrognosisRNA, Long NoncodingSupervised Machine LearningYoung AdultNPM1 protein, humanNucleophosminRNA, Long Noncoding
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY-NC
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.